title: Reversible posterior leukoencephalopathy syndrome induced by axitinib.
authors.affiliation: Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France.
authors.forename: Antonin
authors.initials: A
authors.lastname: Levy
authors.affiliation: Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France.
authors.forename: Lyes
authors.initials: L
authors.lastname: Benmoussa
authors.affiliation: Department of Radiology, Gustave Roussy Institute, Paris XI University, Villejuif, France.
authors.forename: Samy
authors.initials: S
authors.lastname: Ammari
authors.affiliation: Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Albiges
authors.affiliation: Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France. Electronic address: escudier@igr.fr.
authors.forename: Bernard
authors.initials: B
authors.lastname: Escudier
mesh_terms: D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007191:Indazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib; D017479:Receptors, Platelet-Derived Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor
keywords: Axitinib; Clear-cell renal adenocarcinoma; Reversible posterior leukoencephalopathy syndrome; Side-effect; Vascular endothelial growth factor